GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 89bio Inc (NAS:ETNB) » Definitions » EV-to-FCF

89bio (ETNB) EV-to-FCF : -2.03 (As of Jun. 05, 2024)


View and export this data going back to 2019. Start your Free Trial

What is 89bio EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, 89bio's Enterprise Value is $281.60 Mil. 89bio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-138.82 Mil. Therefore, 89bio's EV-to-FCF for today is -2.03.

The historical rank and industry rank for 89bio's EV-to-FCF or its related term are showing as below:

ETNB' s EV-to-FCF Range Over the Past 10 Years
Min: -11.03   Med: 0   Max: 1.33
Current: -1.76

During the past 6 years, the highest EV-to-FCF of 89bio was 1.33. The lowest was -11.03. And the median was 0.00.

ETNB's EV-to-FCF is ranked worse than
100% of 379 companies
in the Biotechnology industry
Industry Median: 8.31 vs ETNB: -1.76

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-05), 89bio's stock price is $8.17. 89bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.010. Therefore, 89bio's PE Ratio for today is At Loss.


89bio EV-to-FCF Historical Data

The historical data trend for 89bio's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

89bio EV-to-FCF Chart

89bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial -10.52 -6.06 -1.75 -5.87 -3.79

89bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.53 -9.18 -6.10 -3.79 -4.13

Competitive Comparison of 89bio's EV-to-FCF

For the Biotechnology subindustry, 89bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


89bio's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 89bio's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where 89bio's EV-to-FCF falls into.



89bio EV-to-FCF Calculation

89bio's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=281.598/-138.821
=-2.03

89bio's current Enterprise Value is $281.60 Mil.
89bio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-138.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


89bio  (NAS:ETNB) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

89bio's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=8.17/-2.010
=At Loss

89bio's share price for today is $8.17.
89bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.010.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


89bio EV-to-FCF Related Terms

Thank you for viewing the detailed overview of 89bio's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


89bio (ETNB) Business Description

Traded in Other Exchanges
N/A
Address
142 Sansome Street, Second Floor, San Francisco, CA, USA, 94104
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Executives
Kathleen Laporte director
Rohan Palekar director, officer: Chief Executive Officer 201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Atkinson Edward Morrow Iii director C/O 89BIO, INC., 142 SANSOME STREET, SECOND FLOOR, SAN FRANCISCO CA 94104
Quoc Le-nguyen officer: See Remarks 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Ryan Martins officer: Chief Financial Officer 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Michael R Hayden director C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Nexus Fund, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ram Waisbourd officer: See Remarks 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Gregory Grunberg director, 10 percent owner 100 BEAVER STREET, WALTHAM MA 02453
Anat Naschitz director, 10 percent owner 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Longitude Capital Partners Iii, Llc 10 percent owner 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Lota S. Zoth director 334 CR 692, BUFFALO GAP TX 79508
Steven Altschuler director MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026